Although macrophage infiltration is impor tant in renal injury that includes glome rulonephritis, 1 appropriate leukocyte recruitment and activation are also a vital step in reparative tissue responses. Persistent tubulointerstitial and glomerular macrophage infi ltration is a hallmark of chronic infl ammatory disease and a feature of many progressive renal diseases. Immunosuppression may interrupt the natural history of renal inflammatory disease but is often incompletely eff ective and is associated with treatment-related complications. Th ere is much research examining the immune mechanisms underlying chronic infl ammation and the associated inade quacy of disease resolution pathways, and it is hoped that identification of some of the cues responsible for limiting active infl ammation and initiating the resolution phase will lead to novel targeted therapies capable of aborting infl ammatory disease with an improved side-eff ect profi le. One putative ' anti-infl ammatory and resolution signal ' is the release of free extracellular adenosine, generated in response to metabolic stress and cell damage in renal ischemia or infl ammation. Adenosine A 2A receptors (A 2A Rs) are expressed across multiple cell lineages in vivo , including endothelium, epithelium, and multiple leukocyte subsets. Ligation of leukocyte A 2A R is associated with the opposition of infl ammatory activation; hence the adenosine -receptor system can be viewed as an elegant endogenous feedback system opposing persisting and injurious immune activation with promotion of the switch to a resolution phenotype.
Garcia et al. 2 (this issue) present work detailing the impact of pharmacological A 2A R agonism and antagonism on the outcome of established proteinuric antiglomerular basement membrane (anti-GBM) nephritis with drug treatment commenced 14 days aft er disease initiation. Th e data presented build on their previous work showing that A 2A R agonism from the time of disease initiation reduced disease severity. 3 Th e initiation of treatment in established disease used in the current study off ers a better analogy to the typical presentation and treatment of patients with rapidly progressive glomerulonephritis and enhances the translational importance of the fi ndings.
Garcia et al. 2 report that the administration of the A 2A R agonist CGS 21680 has a prompt and sustained impact in lessening proteinuria and prevents progressive elevation in serum creatinine. CGS 21680treated animals exhibited reduced disease severity with a remarkable reduction in glomerular macrophage infi ltration associated with reduced levels of the chemokine CCL22 as well as reduced osteopontin, thrombospondin, and transforming growth factor-mRNA levels. Notably, in kidneys treated with the agonist for 6 days, there was a reversal of established fi brosis with reduced expression of collagens III and IV and reduced interstitial myofibroblast accumulation. In contrast, A 2A R antagonism worsened disease outcome.
Th e mechanistic importance of macrophage recruitment in mediating tissue injury and subsequent fi brosis in experimental models of renal disease that includes anti-GBM nephritis is well recognized, as is its contribution to progression of human renal disease. Th us it seems likely that the marked reduction in macrophage infi ltration evident in CGS 21680-treated animals is of major significance. However, the diverse expression profi le of the A 2A R in vivo complicates definitive conclusions regarding the key cellular target of CGS 21680 in mediating the protected phenotype reported, and it thus remains possible that reduced macrophage infi ltration is an epiphenomenon refl ecting reduced tissue injury mediated by alternative, possibly multiple pathways. In order to draw defi nitive conclusions regarding the relative contributions of leukocyte and macrophage A 2A R activation to disease phenotype, studies involving bone marrow transplantation or cell lineage-restricted A 2A R activation or deletion will be necessary.
THE IMPACT OF A 2A R ACTIVATION ON OUTCOME IN EXPERIMENTAL INFLAMMATION
Th e generation of A 2A R knockout mice and the development of pharmacological A 2A R agonists and antagonists have permitted exploration of the infl uence of A 2A R activation and blockade on outcome in diverse experimental models of infl ammation (reviewed by Hasko and Pacher 4 ). A 2A R agonism ameliorates classical chronic infl ammatory conditions such as asthma, autoimmune hepatitis, and infl ammatory bowel disease, and acute infl ammation in ischemia -reperfusion injury of the heart, lung, and liver. Macrophages express A 2A R, and an extensive literature documents the impact of pharmacological A 2A R activation on classical activation in vitro and in vivo (reviewed by Hasko et al. 5 ). Interestingly, Garcia et al. 2 indicate that A 2A R agonism markedly prevents macrophage accumulation at the day 20 time point, with limi ted alteration in the ratio between markers of M1 and M2 macrophage phenotype. It is suggested that reduced CCL22 expression is key to the diminished macrophage accumulation, but it is also possible that reduced macrophage proliferation in situ , or indeed increased emigration to regional lymphoid structures or death in situ , may also be involved.
A 2A R agonism has proved effi cacious in models of acute kidney injury and progressive anti-GBM nephritis and diabetic nephropathy. 3, 6, 7 While reduced macrophage infi ltration has oft en been noted in conjunction with these protected phenotypes, it is noteworthy that macrophage numbers were signifi cantly reduced by A 2A R agonism without any beneficial eff ect on renal scarring in the unilateral ureteric obstruction model. 8 Highlighting the pleiotropic renal eff ects of adenosine, A 2A R agonists and antagonists have been reported to modulate both renal macrophage number and phenotype, neutrophil recruitment 7 and tubuloglomerular feedback, 9 while in vitro evidence suggests that A 2A R agonists may help preserve podocyte structure and function in response to toxic insults. 10 Accordingly, interventions with A 2A R-targeting agents may be infl uencing renal outcome via alterations of immune-cell number and phenotype, direct actions on parenchymal cells, or alterations of systemic and regional hemodynamics (summarized in Figure 1 ) , with the relative importance of each uncertain, and potentially varying between experimental models.
IMMUNE MODULATION AS A THERAPEUTIC GOAL
Although macrophages are important eff ectors of renal injury, there is increasing experimental evidence demonstrating their role in facilitating the successful resolution of tissue injury in the kidney 11 as well as the heart and liver. 12, 13 Conversely, depletion of macrophage populations during tissue repair impedes reparative responses and the resolution of fi brosis. 11, 12 Th is has implications for novel treatments such as A 2A R agonists that may markedly reduce macrophage numbers in diseased tissues, as they may also act to limit the ability of macrophage populations to subsequently eff ect optimal tissue repair.
Recent work by Lee et al. demonstrates a macrophage ' phenotypic switch ' to M2 polarization as a facultative step in the restoration of tissue integrity after renal ischemia -reperfusion injury. 14 Th is pattern echoes the albeit moderate alteration in M1 / M2 macrophage marker profile induced by A 2A R activation that is reported by Garcia et al. , 2 raising the intriguing possibility that such a switch (or its failure) is of particular importance in determining whether an infl ammatory insult persists or resolves. M1 activated macrophages constitute a major line of innate immune defense against pathogens, and it is pertinent that pharmacological inactivation of A 2A R improves outcome aft er experimental polymicrobial sepsis. 15 Accordingly, it will be important to determine whether A 2A R agonists exert a converse effect on outcome after sepsis if translational use is contemplated. It is striking that A 2A R activation remains benefi cial even in a focus of acutely infl amed renal tissue, indicating that the A 2A receptor system remains incompletely saturated even in an environment with presumably high levels of endogenous free adeno sine. Whether additional combinatorial selective activation of other adenosine receptor family proteins would confer addi tional benefits may be the subject of future investigation.
THE IMPORTANCE OF TIMING: IS THERE A WINDOW OF THERAPEUTIC OPPORTUNITY?
Before the current study, attempts to modify the course of experimental glome rular disease in rats using A 2A R activation administered drug treatment from the point of initial renal insult (administration of nephrotoxic serum or initiation of diabetes). In each case this treatment largely aborted the development of the histological and phenotypic markers of disease. 3, 6 Almost invariably, the clinical presentation of glomerular disease occurs some time aft er the fi rst immunological and subsequent histological abnormality has occurred. It remains unknown whether early intervention with a limited period of A 2A R agonism will be suffi cient to initiate eff ective and sustained anti-infl ammatory programming and tissue repair or whether prolonged administration will be necessary to prevent or retard disease progression.
Garcia et al. 2 show that, at least at the time point studied, the development of renal fi brosis (as indicated by collagen III and IV deposition) is a dynamic process, which can be either opposed or potentiated by activation or blockade of the A 2A R system, respectively. Th e documented changes in mRNA expression of transforming growth factor-and thrombospondin (a transforming growth factor-activator) as well as the ratio of MMP2 to TIMP-1 provide a putative mechanism to promote increased matrix turnover with a net reduction in matrix deposition. Evidence from the carbon tetrachloride model of murine hepatic fi brosis indicates that macrophages are essential eff ector cells in the resolution of liver fi brosis and that collagen resorption remains possible aft er a 12-week administration of the profi brotic agent. 12 Whether there is a therapeutic window beyond which renal fi brosis becomes irreversible remains uncertain, and establishing this will require further studies.
An additional consideration of relevance to both the interpretation of experimental A 2A R activation and the potential translational application of these agents relates to the impact of these agents on systemic blood pressure. Th e rapid reduction in proteinuria within 48 h of the commencing of CGS 21680 would support blood pressure reduction as accounting for at least a component of the reduced protein excretion. Th ese hemodynamic eff ects have limited the clinical applications of A 2A R agonists in myocardial perfusion imaging and may call for innovative pharmacological solutions such as the generation of prodrugs that are specifi cally activated at sites of active infl ammation. 16 
CONCLUSION
Th e ultimate goal of the nephrologist is the safe induction of a complete and lasting remission of renal disease. Th e emerging fi eld of regenerative medicine has added to this already daunting challenge the even more ambitious aim of restoring structure and function to the scarred failing kidney. Th is target remains distant and requires further expansion of our incomplete knowledge of the initiating and perpetuating insults that account for the diverse path o logies underlying progressive disease, which probably encompass both the adaptive and the innate arms of the immune response. Th erapies targeting both macrophage number and phenotype as a ' common eff ector ' pathway of renal damage, conserved across many of these pathologies, represent an attractive goal. It may be that A 2A R agonists could form a future component of a mechanistically targeted combination therapy, in association with tolerogenic stimuli or targeted depletion of plasma cells or injurious lymphocyte subsets. Th e study by Garcia et al. 2 gives cause for optimism regarding the potential role of A 2A R agonism in the treatment of renal disease, and a mandate for further translational work.
